Andrew Charles Wotherspoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew Charles Wotherspoon has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
H Liu
Department of Pathology, University of Cambridge, Cambridge, UK
2 shared publicationsH Ye
Department of Pathology, University of Cambridge, Cambridge, UK
2 shared publicationsAhmet Dogan
1 shared publication- Ahmet Dogan
Department of Histopathology, University College London, London, UK
1 shared publication - C.F. Ng
Department of Surgery, Singapore General Hospital, Singapore and
1 shared publication - Cyril Fisher
Department of Histopathology, The Royal Marsden Hospital, London, UK
1 shared publication
Latest Publications
- 24 April 2008
- Published by Wiley in Histopathology
- Vol. 52 (6) , 777-780
t(11;18)(q21;q21)-positive transformed MALT lymphoma
- 24 April 2008
- Published by Wiley in Histopathology
- Vol. 52 (6) , 777-780
t(11;18)(q21;q21)-positive transformed MALT lymphoma
- Open Access
- 7 January 2004
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 2 (1) , 1
Small bowel gastrointestinal stromal tumours and ampullary cancer in Type 1 neurofibromatosis
Type 1 neurofibromatosis (NF-1) is an autosomal dominant disorder with variable penetrance; approximately 50% of cases present as new mutations We report a case of a 56 year-old man with Von Recklinghausen's disease, carcinoma of the ampulla of Vater and incidental benign gastrointestinal stromal tumours of the jejunum. Coexistence between ampullary carcinoid, ectopic pancreatic tissue in the jejunum and neurofibroma of the jejunum in NF-1 has been previously described however; the association of synchronous carcinoma of the ampulla of Vater and gastrointestinal stromal tumour of the jejunum in NF-1 has not been previously reported.
- 7 January 2004
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 2 (1) , 1
Open AccessSmall bowel gastrointestinal stromal tumours and ampullary cancer in Type 1 neurofibromatosis
Type 1 neurofibromatosis (NF-1) is an autosomal dominant disorder with variable penetrance; approximately 50% of cases present as new mutations We report a case of a 56 year-old man with Von Recklinghausen's disease, carcinoma of the ampulla of Vater and incidental benign gastrointestinal stromal tumours of the jejunum. Coexistence between ampullary carcinoid, ectopic pancreatic tissue in the jejunum and neurofibroma of the jejunum in NF-1 has been previously described however; the association of synchronous carcinoma of the ampulla of Vater and gastrointestinal stromal tumour of the jejunum in NF-1 has not been previously reported.
- 1 January 2002
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (1) , 50-55
Mucosa-associated lymphoid tissue lymphoma
Since the first description of mucosa-associated lymphoid tissue (MALT) lymphoma in 1983 rapid advances have been made in the understanding of the pathogenesis and underlying molecular events associated with the development of this tumor. Lymphoma arises at extranodal sites in which a pre-existing inflammatory response has provoked the acquisition of organized lymphoid tissue. Specific molecular events have been associated with the development of MALT lymphoma including t(11;18) and alterations in Bcl-10 protein expression, and these appear to be interlinked. In gastric MALT lymphoma Helicobacter pylori is the most common stimulus for the acquisition of lymphoid tissue. Eradication of this organism has been shown to result in regression of the tumor in many cases, but there are a few that will not respond to this approach. Predicting those cases unlikely to respond to H pylori eradication alone has been investigated in a number of ways. An underlying t(11;18) within the tumor cells appears to predict for a lack of response. Clinical measurement of the depth of infiltration of the wall by gastric MALT lymphoma as measured by endoscopic ultrasound has been less clear. More superficial tumors are more likely to respond, but regression has been reported even in cases with local lymph node involvement. For superficial lymphomas at other sites alternatives to radiotherapy, chemotherapy, or surgery have been sought. Local injections of interferon (IF) alpha have been successful in treating conjunctival lymphoma, and this approach may be of use for other superficial lesions.
- 1 January 2002
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (1) , 50-55
Mucosa-associated lymphoid tissue lymphoma
Since the first description of mucosa-associated lymphoid tissue (MALT) lymphoma in 1983 rapid advances have been made in the understanding of the pathogenesis and underlying molecular events associated with the development of this tumor. Lymphoma arises at extranodal sites in which a pre-existing inflammatory response has provoked the acquisition of organized lymphoid tissue. Specific molecular events have been associated with the development of MALT lymphoma including t(11;18) and alterations in Bcl-10 protein expression, and these appear to be interlinked. In gastric MALT lymphoma Helicobacter pylori is the most common stimulus for the acquisition of lymphoid tissue. Eradication of this organism has been shown to result in regression of the tumor in many cases, but there are a few that will not respond to this approach. Predicting those cases unlikely to respond to H pylori eradication alone has been investigated in a number of ways. An underlying t(11;18) within the tumor cells appears to predict for a lack of response. Clinical measurement of the depth of infiltration of the wall by gastric MALT lymphoma as measured by endoscopic ultrasound has been less clear. More superficial tumors are more likely to respond, but regression has been reported even in cases with local lymph node involvement. For superficial lymphomas at other sites alternatives to radiotherapy, chemotherapy, or surgery have been sought. Local injections of interferon (IF) alpha have been successful in treating conjunctival lymphoma, and this approach may be of use for other superficial lesions.
- 1 November 2000
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 2 (6) , 494-498
A critical review of the effect of Helicobacter pylori eradication on gastric MALT lymphoma
- 1 November 2000
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 2 (6) , 494-498
A critical review of the effect of Helicobacter pylori eradication on gastric MALT lymphoma
- 15 June 2000
- Vol. 95 (12) , 3885-90
BCL10 gene mutation in lymphoma.
BCL10 is directly involved in t(1;14)(p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. Wild-type BCL10 promoted apoptosis and suppressed malignant transformation in vitro, whereas truncated mutants lost the pro-apoptotic activity and exhibited gain of function enhancement of transformation. We studied 220 lymphomas for genomic BCL10 mutation by polymerase chain reaction-single-strand conformational polymorphism and DNA sequencing. Nineteen mutations were found in 13 lymphoma specimens, as follows: 8 of 120 (6.7%) mucosa-associated lymphoid tissue (MALT) lymphomas, 4 of 42 (9.5%) follicular lymphomas, and 1 of 23 (4.3%) diffuse large B-cell lymphomas. No mutations were found in 14 mantle cell lymphomas or 21 T-cell lymphomas. High-grade MALT lymphoma tended to show a slightly higher mutation frequency (2 of 25, 8%) than low-grade MALT tumor (6 of 95, 6.3%). Among low-grade gastric MALT lymphoma, mutations were found in 3 of 11 tumors that did not respond to Helicobacter pylori eradication therapy, but none were found in 22 tumors that regressed completely after H pylori eradication. All 14 potentially pathogenic mutations were distributed in the carboxyl terminal domain of BCL10. Deletion accounted for 10 of these mutations; 10 of 14 mutations caused truncated forms of BCL10. Western blot analysis of a mutant case confirmed the presence of truncated BCL10 products of anticipated size. Our results suggest that BCL10 mutation may play a pathogenic role in B-cell lymphoma development, particularly in aggressive and antibiotic unresponsive MALT lymphomas, and may further implicate the biologic importance of the carboxyl terminal of the molecule. (Blood. 2000;95:3885-3890)
- 15 June 2000
- Vol. 95 (12) , 3885-90
BCL10 gene mutation in lymphoma.
BCL10 is directly involved in t(1;14)(p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. Wild-type BCL10 promoted apoptosis and suppressed malignant transformation in vitro, whereas truncated mutants lost the pro-apoptotic activity and exhibited gain of function enhancement of transformation. We studied 220 lymphomas for genomic BCL10 mutation by polymerase chain reaction-single-strand conformational polymorphism and DNA sequencing. Nineteen mutations were found in 13 lymphoma specimens, as follows: 8 of 120 (6.7%) mucosa-associated lymphoid tissue (MALT) lymphomas, 4 of 42 (9.5%) follicular lymphomas, and 1 of 23 (4.3%) diffuse large B-cell lymphomas. No mutations were found in 14 mantle cell lymphomas or 21 T-cell lymphomas. High-grade MALT lymphoma tended to show a slightly higher mutation frequency (2 of 25, 8%) than low-grade MALT tumor (6 of 95, 6.3%). Among low-grade gastric MALT lymphoma, mutations were found in 3 of 11 tumors that did not respond to Helicobacter pylori eradication therapy, but none were found in 22 tumors that regressed completely after H pylori eradication. All 14 potentially pathogenic mutations were distributed in the carboxyl terminal domain of BCL10. Deletion accounted for 10 of these mutations; 10 of 14 mutations caused truncated forms of BCL10. Western blot analysis of a mutant case confirmed the presence of truncated BCL10 products of anticipated size. Our results suggest that BCL10 mutation may play a pathogenic role in B-cell lymphoma development, particularly in aggressive and antibiotic unresponsive MALT lymphomas, and may further implicate the biologic importance of the carboxyl terminal of the molecule. (Blood. 2000;95:3885-3890)